Abstract
Objectives
This study investigated the clinical efficacy and safety of oral Janus kinase inhibitors (JAKis) in the treatment of hospitalized patients with COVID-19.
Methods
The PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched for relevant articles written before January 29, 2022. Only randomized controlled trials (RCTs) that assessed the clinical efficacy and safety of oral JAKis in patients with COVID-19 were included.
Results
In the pooled analysis of the 7 RCTs, the all-cause 28-day mortality rate in the study group receiving JAKis was significantly lower than that in the control group (9.4% [183/1941] vs. 10.9% [184/1687], risk ratio [RR] = 0.69, 95% confidence interval [CI], 0.58–0.81, I2 = 0%). In addition, the risk of 14-day mortality was in the study group was lower than that in the control group (RR = 0.65, 95% CI, 0.46–0.92, I2 = 0%). Finally, the study group and the control group exhibited similar risks of any adverse events (RR = 0.96, 95% CI, 0.89–1.04, I2 = 0%).
Conclusions
Oral JAKis can significantly reduce the risk of death among patients with COVID-19. In addition, JAKis are tolerable for hospitalized patients with COVID-19.
【저자키워드】 COVID-19, Mortality, mechanical ventilation, Janus kinase inhibitors, 【초록키워드】 Randomized controlled trial, Treatment, 28-day mortality, risk, database, adverse event, oral, RCTs, Janus kinase inhibitor, Clinical efficacy, Analysis, risk of death, control group, 95% CI, 95% confidence interval, article, significantly lower, objective, Result, significantly, addition, investigated, receiving, exhibited, searched, hospitalized patient, reduce, Controlled, patients with COVID-19, the study group, tolerable, with COVID-19, 【제목키워드】 Randomized controlled trial, Meta-analysis, systematic review, oral, Janus kinase inhibitor, hospitalized patient,